Bone regenerative properties of injectable PGLA-CaP composite with TGF-beta1 in a rat augmentation model.
The aim of this study was to examine the bone augmentation properties of an injectable composite consisting of PLGA microspheres/CaP cement (20/80), and the additional effect of loading PLGA microspheres with TGF-beta1 (200 ng). For this purpose, PLGA/CaP composites (control) and PLGA/CaP composites loaded with TGF-beta1 (test group) were injected on top of the skulls of 24 Wistar rats. Each rat received 2 materials from the same experimental group, and in total 48 implants were placed (n = 8). After 2, 4, and 8 weeks the results were evaluated histologically and histomorphometrically. The contact length between the implants and newly formed bone increased in time, and was significantly higher for the TGF-beta1-loaded composites after 2 weeks. Also, bone formation was significantly higher for the TGF-beta1-loaded composites (18.5% +/- 3) compared to controls (7.21% +/- 5) after 8 weeks of implantation. Immunohistochemical staining demonstrated massive inflammatory infiltrates in both groups, particularly at 2 weeks, which decreased substantially at 4 and 8 weeks. In conclusion, injectable PLGA/CaP composites stimulated bone augmentation in a rat model. The addition of TGF-beta1 to the composite significantly increased bone contact at 2 weeks and enhanced new bone formation at 8 weeks.
Plachokova
Adelina
A
Radboud University Nijmegen Medical Centre, Department of Periodontology and Biomaterials, Nijmegen, The Netherlands.
Link
Dennis
D
van den Dolder
Juliette
J
van den Beucken
Jeroen
J
Jansen
John
J
D000818:Animals; D015703:Antigens, CD; D001861:Bone Regeneration / Q000187:drug effects*; D001842:Bone and Bones / Q000166:cytology / Q000187:drug effects; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation; D007267:Injections; D019344:Lactic Acid / Q000008:administration & dosage* / Q000494:pharmacology*; D008297:Male; D023421:Models, Animal; D010012:Osteogenesis / Q000187:drug effects*; D011100:Polyglycolic Acid / Q000008:administration & dosage* / Q000494:pharmacology*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D019904:Polymethyl Methacrylate; D051381:Rats; D017208:Rats, Wistar; D054457:Tissue Scaffolds; D053773:Transforming Growth Factor beta1 / Q000494:pharmacology*
D015703:Antigens, CD; D002130:Calcium Phosphates; D053773:Transforming Growth Factor beta1; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D019904:Polymethyl Methacrylate